Pfizer – Approaches to Implement Bispecific Antibodies into Clinical Practice, Increase Awareness and Improve Delivery of Quality of Care for Patients with Multiple Myeloma – RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire within unit
Memorial Deadline: Thursday 25th, May 2023
External Deadline: Thursday 1st, June 2023
Description
Myeloma Canada and Pfizer Canada are pleased to collaborate to offer a grant opportunity to support Quality Improvement (QI) projects that will advance the quality of care and best practices around treatment for patients with relapsed/refractory multiple myeloma (RRMM) receiving bispecific antibody (BsAb) treatment.
This RFP is being issued by both organizations. Myeloma Canada is the lead organization for review and evaluation of proposals. A review committee, led by Myeloma Canada, will make decisions on which proposals will receive funding. For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program. |
Date RFP Issued: March 15, 2023
Geographic Scope: Canada Clinical Area: Relapsed/Refractory Multiple Myeloma Application Due Date: June 1, 2023 Specific Area of Interest: The intent of this RFP is to support QI initiatives that will increase equitable access to and delivery of quality care for patients with multiple myeloma with the goal of optimizing the care and outcomes of patients. Proposals in the following topic areas are strongly encouraged:
|
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Myeloma Canada’s Director of Science & Research, Gabriele Colasurdo (gcolasurdo@myeloma.ca) or Pfizer’s Grant Officer, Amanda Kaczerski (Amanda.Kaczerski@pfizer.com).